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Abstract
Background: Ubiquitination and ubiquitin-like protein post-translational modifications play an enormous number of
roles in cellular processes. These modifications are constituted of multistep reaction cascades. Readily implementable and
robust methods to evaluate each step of the overall process, while presently limited, are critical to the understanding and
modulation of the reaction sequence at any desired level, both in terms of basic research and potential therapeutic drug
discovery and development.
Results: We developed multiple robust and reliable high-throughput assays to interrogate each of the sequential discrete
steps in the reaction cascade leading to protein ubiquitination. As models for the E1 ubiquitin-activating enzyme, the E2
ubiquitin-conjugating enzyme, the E3 ubiquitin ligase, and their ultimate substrate of ubiquitination in a cascade, we
examined Uba1, Rad6, Rad18, and proliferating cell nuclear antigen (PCNA), respectively, in reconstituted systems.
Identification of inhibitors of this pathway holds promise in cancer therapy since PCNA ubiquitination plays a central role
in DNA damage tolerance and resulting mutagenesis. The luminescence-based assays we developed allow for the
quantitative determination of the degree of formation of ubiquitin thioester conjugate intermediates with both E1 and E2
proteins, autoubiquitination of the E3 protein involved, and ubiquitination of the final substrate. Thus, all covalent adducts
along the cascade can be individually probed. We tested previously identified inhibitors of this ubiquitination cascade,
finding generally good correspondence between compound potency trends determined by more traditional low-
throughput methods and the present high-throughput ones.
Conclusions: These approaches are readily adaptable to other E1, E2, and E3 systems, and their substrates in both
ubiquitination and ubiquitin-like post-translational modification cascades.
Keywords: Ubiquitination, Ubiquitin-like proteins, Post-translational modifications, E1 ubiquitin-conjugating enzymes, E2
ubiquitin-conjugating enzymes, E3 ubiquitin ligases, Step-specific assays and evaluation, High-throughput screening
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Background
Post-translational modification of proteins through ubi-
quitination controls not only protein degradation by the
proteasome but also myriad other processes. Ubiquitin
and related ubiquitin-like proteins (UBLs) serve as tags
and docking sites for protein–protein interactions that
regulate a staggering array of biological pathways.
Modulating various steps of ubiquitination and UBL
post-translational modification pathways with small-
molecule inhibitors or activators/enhancers has consid-
erable research and therapeutic potential. One such
function for ubiquitin and UBLs is in the dynamic con-
trol of the DNA damage repair and tolerance machinery.
DNA damage tolerance pathways evolved to circumvent
the fact that DNA sites altered by chemical insult, oxida-
tion, photodamage, or irradiation that have not been
repaired by other DNA repair mechanisms (such as base
and nucleotide excision or mismatch repair) cause the
stalling of the DNA replication fork. Replicative DNA
polymerases are unable to copy damaged DNA. There
are two general pathways of DNA damage tolerance:
translesion DNA synthesis (TLS) and template switch-
ing. However, TLS is inherently prone to introducing
point mutations, whereas template switching can result
in chromosomal rearrangements. DNA damage toler-
ance can thus lead to genetic alterations, oncogenesis,
formation of secondary tumors after treatment with
DNA-damaging therapeutics, drug resistance, and other
pathologies, with strong evidence that inhibition of the
DNA damage response can lead to reversal of drug re-
sistance in and apoptotic death of a range of different
cancer cell types (reviewed in refs. [1–6]).
The ubiquitination of proliferating cell nuclear antigen
(PCNA), a sliding clamp complex critical to DNA repli-
cation and repair, on a specific lysine residue (K164) is a
key step in the activation of the DNA damage tolerance
pathways. PCNA forms a homotrimeric ring encircling
DNA, binding and coordinating the activities of a broad
range of proteins, including DNA polymerases and many
replication, repair, and regulatory factors (reviewed in
refs. [7–11]). Monoubiquitination of PCNA triggers the
TLS pathway, whereas further polyubiquitination of this
ubiquitin moiety (linked to ubiquitin’s K63 residue, ra-
ther than the K48 involved in proteasomal degradation)
involves additional factors and initiates the alternative
pathway of template switching. Once loaded onto DNA,
an ATP-dependent process facilitated by replication fac-
tor C (RFC), PCNA becomes capable of being monoubi-
quitinated on K164 by the E2 ubiquitin-conjugating
enzyme Rad6 in complex with the E3 ubiquitin ligase
Rad18, the former being the catalyst and the latter the
adaptor for specific substrate recognition. The ubiquiti-
nation reaction cascade begins with the activation of the
carboxy terminus of ubiquitin, catalyzed by the E1
ubiquitin-activating enzyme Uba1 (also known as
UBE1), through reaction with ATP to form a ubiquitin
adenylate intermediate, with subsequent steps not re-
quiring ATP. The ubiquitin adenylate, still bound to
Uba1, then reacts with a catalytic cysteine residue on
Uba1, resulting in a Uba1~ubiquitin thioester conjugate.
The ubiquitin is subsequently transferred to Rad6 to
generate a Rad6~ubiquitin thioester conjugate. In com-
plex with Rad18, the thioester then reacts with the side-
chain amine of K164 on PCNA to form a more stable
PCNA–ubiquitin isopeptide bond. The Rad6–Rad18
dimer can also autoubiquitinate Rad18 at multiple sites
in vitro and in the cell, which appears to affect its func-
tion, subcellular localization, and stability [12, 13].
The human genome encodes two ubiquitin-specific E1
enzymes, approximately 40 ubiquitin-specific E2 en-
zymes, and over 600 ubiquitin-specific E3 proteins, with
pathway selectivity narrowing as the sequence proceeds,
ultimately involving recognition of a given substrate by a
specific E3 protein. The vast majority of E3 ubiquitin li-
gases, such as Rad18, are of the so-called RING class,
functioning as adaptors between a given E2 protein and a
specific substrate protein, with transfer of ubiquitin from
the E2 protein to the ultimate substrate. There are also
two other types of E3 proteins, the HECT and RING-
Between-RING classes, that themselves also form thioester
conjugates with ubiquitin, as a third and final level of
thioester-forming enzyme to mediate transfer of ubiquitin
to the ultimate substrate (reviewed in refs. [14–17]). In
addition to ubiquitin-specific E1, E2, and E3 proteins,
there are cognate UBL-specific proteins, with some func-
tional overlap between them. There are, therefore, a huge
number of potential pathways to probe.
The high-throughput assays we report here to probe
the PCNA ubiquitination cascade at different levels are
all reconstituted systems, composed of the purified pro-
teins relevant to each specific assay, adapted to the amp-
lified luminescent proximity homogeneous assay (Alpha)
system. The Alpha system has various advantages over
other proximity-based approaches, such as the enzyme-
linked immunosorbent assay (ELISA) and resonance en-
ergy transfer (RET) methods (e.g. fluorescence resonance
energy transfer and bioluminescence resonance energy
transfer) in terms of flexibility, adaptability, and sensitiv-
ity (reviewed in ref. [18]). Unlike conventional ELISAs,
the Alpha system is a solution-phase and homogeneous
assay—not requiring wash and separation steps—and
has greater sensitivity and wider dynamic range. In com-
parison to RET methods, an advantage of the Alpha sys-
tem is that it works without the stringent short distance
and orientation restrictions on the donor–acceptor pair.
Tagging or labeling two proteins (or other molecules)
with any of the many tags or labels recognized by avail-
able Alpha bead coatings is generally enough to develop
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a workable Alpha system, without the laborious trial-
and-error of developing a suitably coupled RET pair
system.
We found the high-throughput Alpha assays for the dif-
ferent steps in the PCNA ubiquitination cascade to be ro-
bust, reliable, and sensitive. We found half-maximal
inhibitory concentration (IC50) values and structure–activ-
ity relationship trends for Uba1 inhibitors we previously
reported [19] as determined by the Alpha assay generally
corresponding to other more traditional methods in terms
of both inhibition of the overall PCNA ubiquitination cas-
cade and Uba1 specifically. Thus, the system performs
well as a screening tool for this reaction sequence and as a
legitimate quantitative method for measuring ubiquitina-
tion and formation of thioester conjugates. The ap-
proaches should be straightforwardly adaptable to other




Starting from conditions we optimized previously for
Western blot analysis and quantitation of PCNA
ubiquitination, as well as gel-based analyses of the for-
mation of Uba1~ubiquitin thioester and Rad6~ubiquitin
thioester conjugates [19], we further refined the recon-
stituted systems for the more sensitive Alpha technology.
We sought to reduce the concentrations of the compo-
nents in the reactions and also optimize the subsequent
detection step of the assays. In the process, we devel-
oped a high-throughput Alpha-based PCNA ubiquitina-
tion assay that balances high sensitivity with low
consumption of reagents, as well as analogous Alpha as-
says to probe Uba1~ubiquitin thioester formation,
Rad6~ubiquitin thioester formation, and Rad18 autoubi-
quitination (Fig. 1).
Optimization of the Alpha assay for PCNA ubiquitination
As a departure point, we began with the conditions we
had found provided virtually complete ubiquitination of
PCNA readily detectable by Western blot analysis [19].
We individually varied concentrations of FLAG-PCNA
(Fig. 2a), biotin-ubiquitin (Fig. 2b), RFC (Fig. 2c), Uba1
(Fig. 2d), and Rad6–Rad18 dimer (Fig. 2e). In each case,
we ascertained optimal concentration ranges for strong
Alpha signals.
Fig. 1 Diagram of the Alpha assays for: a PCNA ubiquitination, b Uba1~ubiquitin thioester formation, c Rad6~ubiquitin thioester formation, and
d Rad18 autoubiquitination
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To investigate miniaturization questions, we evaluated
the reaction done in different volumes (Additional file 1:
Fig. S1). We also investigated the optimal parameters for
Alpha detection after the PCNA ubiquitination reaction,
looking at different dilution factors (Additional file 2:
Fig. S2), donor and acceptor bead concentrations
(Additional file 3: Fig. S3a), donor and acceptor bead ra-
tios (Additional file 3: Fig. S3b), order of addition of
donor and acceptor beads (Additional file 4: Fig. S4),
and bead incubation times prior to detection (Additional
file 5: Fig. S5). We found best results with 10× dilution
and simultaneous addition of donor and acceptor beads.
In terms of signal, while 20 μg/ml yielded stronger sig-
nals, we decided on 10 μg/ml to reduce bead consump-
tion, since it gave good results nonetheless. With regard
to incubation time with beads, longer incubations re-
sulted in better signals.
Based on all the preceding experiments on the PCNA
ubiquitination reaction and the Alpha detection step of
the overall assay, we chose final concentrations, condi-
tions, and procedures that balanced sensitivity and assay
quality with the practical concerns of usage of proteins
and beads, as described in Methods. Under these
adopted conditions, we conducted a kinetics experiment
Fig. 2 Alpha assay for PCNA ubiquitination. Data represent mean and standard deviation (SD) for 3–6 replicate samples in each case. Variable
concentrations of: a FLAG-PCNA, b biotin-ubiquitin (Bio-Ub), c RFC (left and right panels are different concentration ranges from separate
experiments), d Uba1, and e Rad6–Rad18 dimer, with other components in each case held constant as noted in Methods. f Reaction kinetics
under final optimized conditions. Details are described in Methods
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to establish the time course of the reaction, with satur-
ation reached around 2 h at 25 °C (Fig. 2f).
With protein concentrations for the PCNA ubiquitina-
tion cascade and Alpha conditions set, we investigated
the dependence of the PCNA ubiquitination cascade on
ATP concentration, which appeared to become non-
limiting for an incubation of 2 h at 25 °C in the high mi-
cromolar range (Additional file 6: Fig. S6a). We also
probed dimethyl sulfoxide (DMSO) tolerance of the re-
action, as DMSO is the most commonly used carrier
solvent for compound delivery in screening (Additional
file 6: Fig. S6b).
We found Z′ factors had typical values for any given
plate of between 0.6 and 0.9, particularly by robust sta-
tistics, which is less sensitive to outliers than standard
statistics, when comparing positive (with ATP) and
negative (without ATP) control values on each plate, in-
dicating suitability for high-throughput screening.
Strictly standardized mean difference values, signal-to-
noise ratios, signal-to-background ratios, and signal win-
dow values per plate were generally also very good.
Alpha assays for Uba1~ubiquitin, Rad6~ubiquitin, and
Rad18 autoubiquitination
We developed three additional Alpha assays to probe other
steps in the PCNA ubiquitination cascade. First, we adapted
the Alpha system for quantitative evaluation of Uba1~ubi-
quitin thioester formation, again starting with the condi-
tions we previously worked out for gel-based detection [19]
and then refined for Alpha detection. We used a FLAG-
Uba1 construct and individually varied concentrations of
the analytes, FLAG-Uba1 (Fig. 3a), with the decline in sig-
nal at higher concentrations the probable result of the hook
effect (see Discussion), and biotin-ubiquitin (Fig. 3b), find-
ing conditions yielding good results.
Second, we developed an Alpha assay for detection of
the Rad6~ubiquitin thioester conjugate, again starting
from conditions previously developed for gel-based de-
tection [19]. We made a FLAG-Rad6 construct and per-
formed reactions with non-FLAG-tagged Uba1 and
biotin-ubiquitin. We individually varied concentrations
of Rad6 (Fig. 3c) and biotin-ubiquitin (Fig. 3d), again de-
fining conditions that gave satisfactory results.
We then split the two-reaction sequence into two
steps to allow for more narrow screening for direct Rad6
modulators as distinct from those that secondarily affect
Rad6 by instead directly targeting Uba1, with a first step
for Uba1 charging with ubiquitin and then a second step
where the precharged Uba1~ubiquitin was combined
with Rad6 (preincubated with compound in a screening
setting) for the transthioesterification reaction
(Additional file 7: Fig. S7a). We experimented with add-
ing ethylenediaminetetraacetic acid (EDTA) to the
charged Uba1~ubiquitin samples before adding Rad6 to
chelate the Mg2+ and prevent further ATP-dependent
charging of Uba1 with ubiquitin after being mixed with
Rad6 so that the assay would be potentially a yet cleaner
transthioesterification readout to evaluate Rad6~ubiqui-
tin thioester formation solely. This would mitigate the
possibility of picking up false positives from the
Rad6~ubiquitin thioester formation assay that bleed
over and inhibit Uba1 instead. At a final EDTA concen-
tration of 20 mM, the same concentration employed
above to terminate the overall PCNA ubiquitination re-
action sequence before the Alpha step, we found dimin-
ished transthioesterification from Uba1 to Rad6 for
some reason, despite being a reaction not requiring
Mg2+-ATP (Additional file 7: Fig. S7a). We thus recon-
figured the Rad6~ubiquitin thioester formation assay
with less ATP (250 μM) and MgCl2 (500 μM), then var-
ied the concentration of EDTA for quenching Uba1
precharging, with little-to-no effect on the reaction up
to 2 mM EDTA (Additional file 7: Fig. S7b). Another
option for preventing further Uba1 charging would be
adding apyrase to hydrolyze ATP between the steps.
Finally, we developed an Alpha assay for the detection
of Rad18 autoubiquitination. We constructed a FLAG-
Rad18 construct and performed reactions with non-
FLAG-tagged Uba1, Rad6–Rad18 dimer, and biotin-
ubiquitin. Variation of concentrations of FLAG-Rad18
(Fig. 3e) and biotin-ubiquitin (Fig. 3f) for this reaction
was also performed, and we again found conditions that
resulted in good outcomes. We then once more imple-
mented a quench of Uba1 charging with EDTA, as we
did with the Rad6~ubiquitin thioester formation reac-
tion in a split assay (Additional file 7: Fig. S7c),
again allowing for elimination of any bleedover effects of
compound on Uba1.
In choosing conditions for each assay to use for
screening, we balanced the desire to reduce protein con-
centrations with retaining good signals. Flowcharts for
the conditions and procedures for the four Alpha assays
(PCNA ubiquitination, Uba1~ubiquitin thioester forma-
tion, Rad6~ubiquitin thioester formation, and Rad18
autoubiquitination) are shown in Fig. 4.
Evaluation of the performance of the Alpha assays for
PCNA ubiquitination and Uba1~ubiquitin thioester
formation by testing with already identified inhibitors
In addition to evaluating plate quality control metrics,
we further validated the assays with inhibitors of Uba1
we recently discovered [19], a number of different green
tea compounds (structures in Fig. 5). We performed
dose–response experiments with the Alpha assays for
PCNA ubiquitination (Fig. 6) and Uba1~ubiquitin thioe-
ster formation (Fig. 7a and b). The structure–activity re-
lationships were similar to those we previously reported
[19], with generally similar trends in relative calculated
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IC50 values for each of the bioactive compounds, as
shown in Table 1.
Discussion
The PerkinElmer Alpha system is based on the lumines-
cent oxygen channeling immunoassay, a homogeneous
bead-based immunoassay method. High-energy
irradiation at 680 nm excites the photosensitizer
phthalocyanine in the Alpha donor beads, which con-
verts ambient ground-state oxygen to an excited singlet
state (distinct from the far more reactive superoxide rad-
ical), which has a half-life of ~ 4 μs in aqueous solutions
and can diffuse over a distance of up to ~ 200 nm. If an
Alpha acceptor bead is within this distance, the singlet
Fig. 3 Alpha assays for Uba1~ubiquitin thioester formation, Rad6~ubiquitin thioester formation, and Rad18 ubiquitination. Data represent mean
and SD for 5 samples in each case. Variable concentrations of a FLAG-Uba1 and b biotin-ubiquitin (Bio-Ub) in the Uba1~ubiquitin thioester
formation assay, with the other component in each case being held constant. Variable concentrations of c FLAG-Rad6 and d biotin-ubiquitin in
the Rad6~ubiquitin thioester formation assay. Variable concentrations of e FLAG-Rad18 and f biotin-ubiquitin in the Rad18 autoubiquitination
assay. Details for each assay are described in Methods
Fenteany et al. BMC Molecular and Cell Biology           (2020) 21:21 Page 6 of 16
oxygen can react with a thioxene derivative in the ac-
ceptor bead, producing a chemiluminescent emission
that excites fluors also contained in the acceptor beads
(anthracene and rubrene for the version of the assay
known as AlphaScreen or a europium chelate for that
known as AlphaLISA). The resulting fluorescent emis-
sions (520–620 nm or 615 nm for AlphaScreen or
AlphaLISA, respectively) are detected by a photomulti-
plier tube. AlphaLISA acceptor beads, with a more nar-
rowly defined and sharp emission spectrum, are useful
in certain samples, such as serum or plasma, where there
may be components that interfere with the AlphaScreen
emission. In the present study, we employed the
AlphaScreen acceptor beads, but we have also worked
with AlphaLISA acceptor beads in the PCNA ubiquitina-
tion assay and found no difference in performance
between the two versions of the Alpha assay in our
system [19].
We have applied the Alpha system to the PCNA ubi-
quitination cascade, first to the overall process and then
to the different intermediary steps in the reaction se-
quence involving covalent ubiquitin adducts. Modulators
of the different specific components of the PCNA ubi-
quitination cascade can be identified and characterized
in terms of degree of potency readily, allowing for rapid
discovery of both potential research probes and thera-
peutic agents with a broad spectrum of anticancer
activity.
In addition to its utility as a high-throughput screening
method with advantages over RET and ELISA ap-
proaches (reviewed in ref. [18]), the Alpha system is con-
siderably quicker, simpler, and more sensitive than
Western blot analysis and other traditional methods for
low-throughput detection of ubiquitination or ubiquitin
thioester conjugates. We found reasonably good corres-
pondence in compound potency trends between the
Alpha assay and traditional assays (Table 1) with the
Uba1 inhibitors we previously reported [19]. In addition,
the Alpha system has been used to probe components of
other ubiquitination or UBL post-translational modifica-
tion pathways [20–25]. Here we have adapted it to look
at new ultimate substrate modifications (PCNA and
Rad18) and also to evaluate intermediate ubiquitin con-
jugates in the pathway. The approach can be employed
to screen not only for inhibitors but also for activators/
enhancers of these processes, particularly if the screen-
ing is done at reaction times prior to normal attainment
of saturating modification of a substrate.
Optimization of protein and bead concentrations and
other parameters is important in the implementation of
Fig. 4 Flowchart of optimized conditions for each Alpha assay. Stepwise procedures are shown for: a PCNA ubiquitination, b Uba1~ubiquitin
thioester formation, c Rad6~ubiquitin thioester formation, d Rad18 autoubiquitination. Detailed conditions are described in Methods
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an Alpha-based screening effort from the standpoints
of utilizing economical amounts of proteins and beads
while retaining good signal strength and dynamic range.
The overall Alpha assay can be viewed as composed of
two main parts: first, the biochemical process of inter-
est that generates the proximity relationship to be
Fig. 5 Structures of Uba1 inhibitors and their analogs examined in the Alpha assays. The compounds, some of which inhibit Uba1 and
ubiquitination, as we previously reported [19], were: (−)-epigallocatechin-3-gallate (EGCG), (−)-epicatechin-3-gallate (ECG), (−)-epigallocatechin
(EGC), (−)-epicatechin (EC), (+)-catechin (Cat), gallic acid (GA), n-propyl gallate (PG), n-octyl gallate (OG), n-dodecyl (lauryl) gallate (DG), myricetin
(Myr), and (+)-dihydromyricetin (DM)
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assayed; second, the procedures for Alpha detection
(which involves dilution of the initial samples with
addition of beads and then the actual detection itself).
Both of these major steps of the overall assay must be
optimized. We found that while the dynamic signal
range was consistently good, graded, and reproducible,
precise signal intensity values of the range (e.g. between
minimum and maximum signal values or between
negative and positive control values) can vary from ex-
periment to experiment, even under ostensibly identical
conditions; thus, combining data from multiple inde-
pendent experiments should be done only after mean-
ingful normalization. Another point to note is that the
Alpha assay is susceptible to the high-dose hook ef-
fect—wherein too high concentrations of analytes can
result in diminished signals in bimolecular detection as-
says involving saturable reagent binding such as in
AlphaScreen/AlphaLISA, ELISA, and indirect-detection
(e.g. antibody-based) RET systems—which plays into
these considerations. (The hook effect, also referred to
Fig. 6 Effects of compounds in the PCNA ubiquitination Alpha assay. Samples were preincubated with compounds for 15 min prior to initiation
of reactions with ATP. Data represent mean and SD for 3–7 samples in each case. Final DMSO concentration was 1% in all cases. a Dose–
response for bioactive inhibitors of PCNA ubiquitination, plotted both linearly and semi-logarithmically (inset). b Effects of compounds with little
activity against PCNA ubiquitination at 500 μM, normalized to positive (DMSO alone) control values
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as the hooking or prozone effect, is named after the
shape of the analyte concentration–signal curve in such
cases, which resembles a fish hook.) Optimal concen-
trations, conditions, and procedures cannot be pre-
dicted a priori for any given experimental system. They
will depend on factors such as the nature of the ana-
lytes, the analyte-capturing coating on the beads, their
affinities, and the stoichiometries of their interactions.
Optimal assay parameters must therefore be deter-
mined empirically for any given system.
Conclusions
We have developed and validated multiple assays, based
on the powerful Alpha technology, to assess ubiquitina-
tion of a substrate protein and the formation of ubiqui-
tin thioester conjugates involved in the reaction cascade.
We show that PCNA ubiquitination and the intermedi-
ate steps leading to ultimate substrate modification can
be interrogated in a high-throughput manner that also
directly yields externally verifiable results for valid mea-
sures of the potency of inhibitors for discrete steps in
Fig. 7 Effects of compounds in the Uba1~ubiquitin thioester formation Alpha assay. Data represent mean and SD for 3–5 samples in each case.
Final DMSO concentration was 1% in all cases. FLAG-Uba1 samples were preincubated with compounds for 15 min prior to addition of biotin-
ubiquitin and ATP. a Dose–response for bioactive inhibitors of Uba1~ubiquitin thioester formation, plotted both linearly and semi-logarithmically
(inset). b Effects of compounds with little activity against Uba1~ubiquitin thioester formation at 500 μM, normalized to positive (DMSO alone)
control values. Calculated IC50 values for the compounds are shown in Table 1
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the process. The assays are straightforward to imple-
ment, reliable, robust, and quantitative. The approach
can be readily adapted to addressing both overall and




All proteins were of human origin, except for RFC, which
was from Saccharomyces cerevisiae, and were expressed
and purified as previously described [19, 26–29], as de-
tailed below. A sodium dodecyl sulfate (SDS)–polyacryl-
amide gel of representative protein preparations is shown
in Additional file 8: Fig. S8. Biotinylated human ubiquitin
was purchased from Boston Biochem/R&D Systems (UB-
570). Purified pUC19 plasmid was nicked with Nt.BstNBI
(New England Biolabs) at 55 °C overnight. Streptavidin
donor and anti-FLAG acceptor AlphaScreen beads were
from PerkinElmer.
His-tagged Uba1 preparation
His-tagged human Uba1 in the pET3a bacterial expression
vector (Addgene plasmid #63571, courtesy of Titia Sixma)
was expressed in Escherichia coli strain BL21-CodonPlus
(DE3)-RIL (Agilent). The cells were centrifuged and
washed in 1× phosphate-buffered saline (PBS). The cell
suspensions were dropped into liquid nitrogen, and the
resulting frozen beads were ground with a SPEX Sample-
Prep 6775 Freezer/Mill. The lysates were centrifuged, and
the supernatant was applied to a Ni-nitrilotriacetic acid
(NTA) agarose (Machery-Nagel) column. Following re-
peated washings, the protein was eluted from the column
with 250mM imidazole, then dialyzed against 20mM
Tris-HCl, pH 7.5, 150mM NaCl, 10% glycerol, 0.01% NP-
40, and 1mM freshly added dithiothreitol (DTT).
Rad6–Rad18 dimer preparation
Both human Rad6B and glutathione S-transferase (GST)-
fused human Rad18 constructs (each cloned into the
pBJ842 yeast expression vector, which contains Leu and
Trp auxotrophic markers) were introduced into the S. cere-
visiae BJ5654 strain. The cells were grown in omission
media (−Leu, −Trp), then collected when reaching an
OD600 of 0.8–1, centrifuged, and washed with 1× PBS. The
cells were resuspended in yeast lysis buffer consisting of 50
mM HEPES, pH 7.5, 50mM KCl, 300mM NaCl, 10% su-
crose, 0.5mM EDTA, and 2.8mM β-mercaptoethanol).
The cell lysate was then dropped into liquid nitrogen, then
ground with a SPEX SamplePrep 6775 Freezer/Mill, col-
lected into 1.5ml microcentrifuge tubes, and centrifuged.
The supernatant was applied to a glutathione Sepharose 4B
(GE Healthcare) column, followed by repeated washing
with 20mM Tris-HCl, pH 7.5, 10% glycerol, 0.01% NP-40,
and 1mM DTT at progressively lower NaCl concentrations
(3× 500mM, 3× 250mM, 1× 150mM). The GST moiety
was cleaved with PreScission Protease (GE Healthcare) with
incubation for 2 h at 4 °C lightly on a shaker, and the dimer
was eluted with a 1.5× bed volume equivalent of 20mM
Table 1 Half-maximal inhibitory concentration (IC50) values for compounds against PCNA ubiquitination and Uba1~ubiquitin
thioester formation by the Alpha assay compared to other methods. All IC50, standard error (SE), and 95% confidence interval (CI)
values listed were calculated by nonlinear regression with GraphPad Prism software. Ind. = indeterminate
Compound IC50 for inhibition of PCNA
ubiquitination (Alpha)
IC50 for inhibition of PCNA
ubiquitination
(Western blot) [19]
IC50 for inhibition of Uba1~Ub
thioester formation
(Alpha)
IC50 for inhibition of Uba1~Ub
thioester formation (gel-based) [19]
EGCG 0.0566 μM (SE = 0.00954; CI:
0.0409–0.0776)
0.228 μM (SE = 0.0342; CI:
0.171–0.319)
0.488 μM (SE = 0.145; CI:
0.259–0.949)
1.63 μM (SE = 0.458; CI:
0.835–3.45)
ECG 0.0988 μM (SE = 0.0442; CI:
0.0318–0.275)
0.537 μM (SE = 0.0946; CI:
0.375–0.843)
0.769 μM (SE = 0.113; CI:
0.586–1.02)
4.22 μM (SE =
2.16; CI: 1.26–13.78)
EGC 6.62 μM (SE = 3.23; CI:
2.92–16.5)
43.3 μM (SE = 22.8; CI:
16.1–129)
5.96 μM (SE = 17.3; CI:
0.101–Ind.)
7.58 μM (SE = 3.87; CI: 2.93–20.7)
EC > 500 μM > 500 μM > 500 μM > 500 μM
Cat ca. 500 μM > 500 μM > 500 μM > 500 μM
GA > 500 μM > 500 μM > 500 μM > 500 μM
PG > 500 μM > 500 μM > 500 μM > 500 μM
OG 3.08 μM (SE = 0.611; CI:
2.59–6.35)
10.3 μM (SE = 6.41; CI:
3.18–40.1)
13.4 μM (SE = 6.02; CI:
5.34–38.5)
80.6 μM (SE = 33.9; CI: 34.8–405)
DG 3.73 μM (SE = 0.566; CI:
2.83–4.56)
1.63 μM (SE = 0.312; CI:
1.05–2.67)
44.4 μM (SE = 22.4; CI:
18.8–150)
35.0 μM (SE = 25.1; CI: 6.29–533)
Myr 0.760 μM (SE = 0.393; CI:
0.323–2.61)
1.21 μM (SE = 0.208; CI:
0.876–4.20)
1.59 μM (SE = 0.746; CI:
0.721–4.22)
0.721 μM (SE = 0.497; CI: 0.177–2.68)
DM 28.7 μM (SE = 5.30; CI:
19.7–49.5)
66.4 μM (SE = 38.9; CI:
27.2–181)
27.5 μM (SE = 13.6; CI:
7.52–113)
14.3 μM (SE = 3.14; CI: 5.93–22.2)
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Tris-HCl, pH 7.5, 150mM NaCl, 10% glycerol, 0.01% NP-
40, and 1mM DTT.
FLAG-tagged PCNA and FLAG-tagged Uba1 preparation
Constructs of human PCNA bearing GST and FLAG
tags or human Uba1 bearing GST and FLAG tags, both
cloned into the pBJ842 yeast expression vector, were
used to prepare FLAG-tagged PCNA and FLAG-tagged
Uba1 proteins, respectively, with subsequent expression
in the S. cerevisiae BJ5654 strain and purification with
cleavage of the GST moiety, as above.
FLAG-tagged Rad6 and FLAG-tagged Rad18 preparation
Constructs were generated with Gateway cloning tech-
nology (Life Technologies). Human Rad6B and human
Rad18 cDNA sequences from entry constructs were
recombined into a modified pGEX-6P-1 (Amersham)
destination vector bearing GST and FLAG tags with a
Gateway cassette via the LR Clonase II reaction (Invitro-
gen). Proteins were overexpressed in the E. coli strain
BL21-CodonPlus (DE3)-RIL (Agilent). The proteins were
purified with removal of the GST moiety, as above.
RFC preparation
The construct pLANT-2/RIL–RFC[1s + 5] was cotrans-
formed with the construct pET(11a)–RFC[2 + 3 + 4] [26]
into the E. coli strain BL21-CodonPlus (DE3)-RIL (Agi-
lent), where RFC1s represents an N-terminally truncated
form of the large RFC subunit [30]. The cells were
plated and allowed to grow under selection with ampicil-
lin (100 μg/ml) and kanamycin (50 μg/ml) overnight. A
single transformant colony was then picked and grown
in 2 ml of Luria-Bertani medium containing ampicillin
(100 μg/ml) and kanamycin (50 μg/ml) at 37 °C for 8 h,
then inoculated into a started culture of 2 l of Luria-
Bertani medium containing ampicillin (100 μg/ml) and
kanamycin (50 μg/ml) for 16 h. 300 ml of the starter cul-
ture was inoculated into 2 l of Luria-Bertani medium
and grown to an OD600 of 0.8 at 37 °C. The cultures
were cooled down to 16 °C and induced with 0.5 mM
isopropyl-β-D-thiogalactoside for 16 h. All further steps
were performed at 4 °C.
The cells were harvested by centrifugation and then
resuspended in HEG buffer (30 mM HEPES, pH 7.6, 0.5
mM EDTA, 10% glycerol, 5 mM β-mercaptoethanol)
containing 150 mM NaCl. To lyse the cells, lysozyme
was added to 0.4 mg/ml, and the cells were subjected to
three freeze-thaw cycles, followed by mechanical shear-
ing through a hypodermic needle. The cell lysate was
treated with Benzonase endonuclease, purity grade II
(Merck), according to the manufacturer’s protocol. The
cell lysate was clarified by centrifugation. RFC was puri-
fied by chromatography over an SP Sepharose column
(bed volume of 6 ml), pre-equilibrated with HEG
containing 50mM NaCl, followed by wash with 60ml of
HEG buffer containing 50 mM NaCl. Elution was carried
with a gradient of 50–1000 mM NaCl in 60ml of HEG
buffer. Peak fractions were collected, pooled, then di-
luted with Ni-NTA buffer (30 mM HEPES, pH 7.6, 20
mM imidazole, 500mM NaCl, 10% glycerol, 5 mM β-
mercaptoethanol). The resulting sample was then ap-
plied to a Ni-NTA agarose (Machery-Nagel) column
(bed volume of 500 μl), pre-equilibrated with Ni-NTA
buffer. The column was then washed with 5 ml of Ni-
NTA buffer, and proteins were eluted by a three-step
gradient (100 mM, 250 mM, and 500 mM imidazole),
each with 1.5 ml overall volume. Fractions were tested
for PCNA loading ability, and peak fractions were ali-
quoted, frozen in liquid N2, and stored at − 80 °C until
subsequent use.
Alpha assay for PCNA ubiquitination
Reactions were performed in 96-well white round-
bottom polypropylene plates (Greiner Bio-One) in a buf-
fer consisting of 40 mM Tris-HCl, pH 7.5, 8 mM MgCl2,
and 10% glycerol, with protein concentrations as noted
below. Reactions were initiated with ATP added to a
final concentration of 2 mM (unless otherwise noted),
with incubation for 2 h at 25 °C (except for time-course
experiments, where different incubation times were ex-
amined). The samples were then diluted in a buffer of
25 mM HEPES, pH 7.5, 100 mM NaCl, 0.1% Tween 20,
and 1mM DTT (Alpha buffer), containing 20mM
EDTA and streptavidin donor and anti-FLAG AlphaSc-
reen acceptor beads, under low-light conditions with
dark yellow-green filter (LEE 090) covering sources of
lighting. (In the case of time-course experiments, how-
ever, the EDTA, which terminates both the ATP-
dependent PCNA-loading process and the ubiquitination
reaction cascade by chelating Mg2+, was instead added
separately as a prior step until all samples were ready for
Alpha detection.) In the case of the two-part assays involving
quenching of Uba1 charging, EDTA was added to the Uba1
sample before the subsequent components and not with the
donor and acceptor bead solution. Following incubation as
indicated below, plates were read in a Tecan Spark plate
reader (equipped with a dedicated high-energy laser light
source and both cooling-and-heating temperature control
for temperature consistency), with excitation at 680 nm and
measurement of emission at 520–620 nm, as appropriate for
the AlphaScreen acceptor beads.
FLAG-PCNA concentration variation in the PCNA
ubiquitination assay
Different FLAG-PCNA concentrations were tested with
the other reaction components held constant at 2.5 nM
nicked pUC19, 50 nM RFC, 50 nM Uba1, 250 nM Rad6–
Rad18 dimer, and 250 nM biotin-ubiquitin. The
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reactions were initiated by addition of ATP to 2 mM for
a final volume of 20 μl with incubation for 2 h at 25 °C.
(Note: The above conditions, serving as a starting point,
are those we had previously optimized for virtually
complete ubiquitination of PCNA as detected by West-
ern blot analysis [19]). For the Alpha assay itself, the sam-
ples were diluted by a factor of 10× in Alpha buffer with
donor and acceptor beads (20 μg/ml each) and 20mM
EDTA. Following incubation with beads for 1 h at 25 °C,
plates were read in the plate reader (Fig. 2a).
Biotin-ubiquitin concentration variation in the PCNA
ubiquitination assay
Different biotin-ubiquitin concentrations were tested
with the other reaction components held constant at 2.5
nM nicked pUC19, 50 nM RFC, 50 nM Uba1, 250 nM
Rad6–Rad18 dimer, and 50 nM FLAG-PCNA, with the
assay otherwise carried out as above (Fig. 2b).
RFC concentration variation in the PCNA ubiquitination
assay
Different RFC concentrations were tested with the other
reaction components held constant at 2.5 nM nicked
pUC19, 50 nM Uba1, 250 nM Rad6–Rad18 dimer, 50
nM FLAG-PCNA, and 250 nM biotin-ubiquitin, with the
assay carried out otherwise as above (Fig. 2c).
Uba1 concentration variation in the PCNA ubiquitination
assay
Different Uba1 concentrations were tested with the
other reaction components held constant at 2.5 nM
nicked pUC19, 50 nM RFC, 250 nM Rad6–Rad18 dimer,
50 nM FLAG-PCNA, and 250 nM biotin-ubiquitin, with
the assay carried out otherwise as above (Fig. 2d).
Rad6–Rad18 concentration variation in the PCNA
ubiquitination assay
Different Rad6–Rad18 dimer concentrations were tested
with the other reaction components held constant at 2.5
nM nicked pUC19, 50 nM RFC, 50 nM Uba1, 250 nM
Rad6–Rad18 dimer, 50 nM FLAG-PCNA, and 250 nM
biotin-ubiquitin, with the assay carried out otherwise as
above (Fig. 2e).
Optimized protein concentrations for the PCNA
ubiquitination cascade
Based on the above experiments, we standardized on
protein concentrations of 10 nM RFC (though below op-
timal, we wished to lessen usage of the most onerous
component of the system to express and purify), 10 nM
Uba1, 100 nM Rad6–Rad18 dimer, 50 nM FLAG-PCNA,
and 250 nM biotin-ubiquitin for the reaction component
of the assay. The experiments below were thus con-
ducted with these concentrations.
PCNA ubiquitination reaction volumes
Reactions were performed in different reaction volumes
with incubation for 2 h at 25 °C, followed by Alpha de-
tection after 10× dilution in Alpha buffer containing
donor and acceptor beads (20 μg/ml each) and 20mM
EDTA, and incubation in the dark for 4 h at 25 °C prior
to Alpha detection (Additional file 1: Fig. S1), as longer
incubation time with beads resulted in improved signal
(see Additional file 5: Fig. S5). Subsequent reactions
were done in 20 μl, also with incubation in the dark for
4 h at 25 °C.
Dilution factors for detection of ubiquitinated PCNA
Reactions were diluted to different degrees in Alpha buf-
fer containing donor and acceptor beads (20 μg/ml each)
and 20 mM EDTA, with the assay otherwise carried out
as above (Additional file 2: Fig. S2).
Donor and acceptor bead concentrations for detection of
ubiquitinated PCNA
Reactions were diluted 10× in Alpha buffer with differ-
ent equimolar donor and acceptor bead concentrations
and 20 mM EDTA, with the assay otherwise carried out
as above (Additional file 3: Fig. S3a).
Donor and acceptor bead ratios for detection of
ubiquitinated PCNA
Reactions were diluted 10× in Alpha buffer with differ-
ent donor:acceptor bead concentration ratios and 20
mM EDTA, with the assay otherwise carried out as
above (Additional file 3: Fig. S3b).
Donor and acceptor bead order of addition for detection
of ubiquitinated PCNA
Reactions were diluted in stepwise fashion in equal vol-
umes (for final dilution of 10× in Alpha buffer with
donor and acceptor beads at 10 μg/ml final concentra-
tion for each), as follows: (1) donor beads first (with in-
cubation for 2 h), then acceptor beads (with further
incubation for 2 h), or (2) acceptor beads first (with in-
cubation for 2 h), then donor beads (with further incuba-
tion for 2 h), or (3) donor and acceptor beads added
simultaneously (with incubation for 2 or 4 h), all at
25 °C, followed by incubation and Alpha detection
(Additional file 4: Fig. S4).
Donor and acceptor bead incubation times for detection
of ubiquitinated PCNA
After reactions, samples were diluted by 10× in Alpha
buffer containing donor and acceptor beads (10 μg/ml
each) for different lengths of time (30 min to 12 h) be-
fore Alpha detection (Additional file 5: Fig. S5).
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Final optimized conditions for the PCNA ubiquitination
cascade and Alpha detection
In the end, based on the sum of experimental results for
conditions of both the PCNA ubiquitination reaction and
the Alpha detection steps of the overall assay, the final
conditions chosen to balance both optimal assaying and
material usage concerns for the PCNA ubiquitination
assay were: 2 nM nicked pUC19 (we reduced the nicked
pUC19 concentration to an even 2 nM, as the precise
DNA concentration makes little difference to the reac-
tion), 10 nM RFC, 10 nM Uba1, 100 nM Rad6–Rad18
dimer, 50 nM FLAG-PCNA, and 250 nM biotin-ubiquitin;
initiation with 2mM ATP; a reaction volume of 20 μl in
96-well plates, with incubation for 2 h at 25 °C; dilution by
a factor of 10× in Alpha buffer containing donor and ac-
ceptor beads (10 μg/ml each) and 20mM EDTA, with in-
cubation of 4 h in the dark at 25 °C, followed by Alpha
detection. In 384-well plates (with a reaction volume of
10 μl, followed by 10× dilution and Alpha detection as
above), the reaction also proceeded, but with less
consistency.
PCNA ubiquitination reaction kinetics under final
optimized conditions
Reactions were stopped at different time intervals from 0
to 6 h by adding EDTA to 20mM and saved until the
Alpha detection step, at which point the samples were di-
luted 10× in Alpha buffer containing donor and acceptor
beads (10 μg/ml each), incubated for 4 h at 25 °C in the
dark, and Alpha detection was carried out (Fig. 2f).
Titration of the concentration of ATP in the PCNA
ubiquitination cascade
Reactions were incubated in the presence of different con-
centrations of ATP, with the assay carried out under final
optimized conditions as above (Additional file 6: Fig. S6a).
DMSO tolerance of the PCNA ubiquitination cascade
Reactions were incubated in the presence of different con-
centrations of DMSO, with the assay carried out under final
optimized conditions as above (Additional file 6: Fig. S6b).
Alpha assay for Uba1~ubiquitin thioester formation
Concentrations of FLAG-Uba1 with biotin-ubiquitin
concentration held constant at 150 nM (Fig. 3a) were
varied, as were biotin-ubiquitin with FLAG-Uba1 con-
centration held constant at 50 nM (Fig. 3b), under other-
wise identical reaction and assay conditions in a buffer
consisting of 40 mM Tris-HCl, pH 7.5, 8 mM MgCl2,
and 10% glycerol. The reactions were initiated by
addition of ATP to 2 mM for a final volume of 20 μl,
then incubated for 30 min at 25 °C, with reaction termin-
ation and dilution (except for the omission of DTT),
incubation, and Alpha detection carried out under final
optimized conditions as above.
Alpha assay for Rad6~ubiquitin thioester formation
Concentrations of FLAG-Rad6 with biotin-ubiquitin
held constant at 150 nM (Fig. 3c) and biotin-ubiquitin
with FLAG-Rad6 held constant at 50 nM (Fig. 3d) were
each separately varied, under otherwise identical reac-
tion and assay conditions in a buffer of 40 mM Tris-
HCl, pH 7.5, 8 mM MgCl2, and 10% glycerol. The Uba1
concentration was 50 nM in these experiments. The re-
actions were initiated by the addition of 2 mM ATP for
a final volume of 20 μl, incubated for 30 min at 25 °C,
with termination and dilution (except for the omission
of DTT), incubation, and Alpha detection carried out
under final optimized conditions as above.
Once satisfactory starting conditions were found, the
overall reaction was then conducted in two separate
steps, which allows for screening for direct inhibitors of
Rad6~ubiquitin thioester formation whose mechanism is
not just secondary to inhibition of Uba1~ubiquitin
thioester formation (Additional file 7: Fig. S7a). For ini-
tial precharging of Uba1 with biotin-ubiquitin, 100 nM
Uba1 was combined with 300 nM biotin-ubiquitin, with
the reaction initiated by addition of ATP to 2 mM,
followed by incubation for 30 min at 25 °C. The reaction
sample was then combined with an equal volume of 100
nM FLAG-Rad6 (which can be preincubated with com-
pounds for screening for direct Rad6 inhibitors), for final
concentrations of 50 nM Uba1, 150 nM biotin-ubiquitin,
and 50 nM FLAG-Rad6, with a final volume of 20 μl.
The mixture was incubated for another 30 min at 25 °C,
with the remaining procedures as before. To prevent the
possibility of further charging of Uba1 with biotin-
ubiquitin before addition of Rad6, we performed an ex-
periment where the Uba1 sample was quenched with
EDTA prior to mixing with Rad6 (to a final EDTA con-
centration of 20 mM, a concentration which for some
reason negatively affected the transthioesterification re-
action despite this step of the cascade not requiring
Mg2+-ATP, as noted above), with protein concentrations
and incubation times being the same (Additional File 7:
Fig. S7a). Lower concentrations of ATP (250 μM) and
MgCl2 (500 μM), with varying concentrations of EDTA
(500 μM–8 mM), were also examined, with other condi-
tions being the same (Additional File 7: Fig. S7b).
Alpha assay for Rad18 autoubiquitination
Concentrations of FLAG-Rad18 with biotin-ubiquitin
held constant at 150 nM (Fig. 3f) and concentrations of
biotin-ubiquitin with FLAG-Rad18 held constant at 50
nM (Fig. 3g) were each separately varied under other-
wise identical reaction and assay conditions in a buffer
of 40 mM Tris-HCl, pH 7.5, 8 mM MgCl2, and 10%
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glycerol in a volume of 20 μl. Uba1 was held constant at
50 nM, and Rad6–Rad18 dimer was held at 100 nM. The
reaction was incubated at 25 °C for 1 h in Alpha buffer
(which includes DTT in it) containing donor and ac-
ceptor beads at 10 μg/ml each, and the assay was carried
out under final optimized conditions as above.
We applied this two-part procedure also to the Rad18
autoubiquitination assay, wherein we allowed for char-
ging of 100 nM Uba1 and 200 nM biotin-ubiquitin with
250 μM ATP and 500 μM MgCl2 for 30 min at 25 °C,
then quenched the reaction by addition of EDTA to a
final concentration of 1 mM. We mixed the sample with
an equal volume of 200 nM Rad6–Rad18 dimer and 100
or 200 nM FLAG-Rad18, as indicated (for final protein
concentrations of 50 nM Uba1, 100 nM biotin-ubiquitin,
100 nM Rad6–Rad18 dimer, and 50 or 100 nM FLAG-
Rad18), then incubated for an additional 1 h at 25 °C in
Alpha buffer containing donor and acceptor beads at
10 μg/ml each and 20mM EDTA, and the assay was
then carried out under final optimized conditions as
above (Additional file 7: Fig. S7c).
Testing of previously identified inhibitors of
ubiquitination in the Alpha assay
We employed the above optimized conditions and exam-
ined the effect of green tea compounds that we previously
identified as inhibitors of ubiquitination at the level of
Uba1 [19]. Compounds were added to wells in 96-well
plates containing all the components of the reaction ex-
cept for ATP, with preincubation for 15min. ATP was
then added to 2mM to initiate the ubiquitination cascade
with a final volume of 20 μl, and the procedures for reac-
tion and Alpha assay were the optimized ones described
above (Fig. 6). We also conducted Alpha assays for
Uba1~ubiquitin thioester formation, with preincubation
for 15min with the compounds prior to initiation of reac-
tion and assay, as described above (Fig. 7a and b).
Statistical analysis
Statistical analysis was performed with Microsoft Excel
and GraphPad Prism 8 software.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12860-020-00262-5.
Additional file 1: Figure S1. PCNA ubiquitination reaction volumes.
PCNA ubiquitination was conducted in different volumes, followed by
incubation in Alpha buffer with donor and acceptor beads and detection.
Data represent mean and SD for 8 samples. For conditions and
procedures for this and subsequent figures, see Methods.
Additional file 2: Figure S2. Dilution factors for detection of
ubiquitinated PCNA. PCNA ubiquitination reactions were diluted to
different degrees as indicated in Alpha buffer with donor and acceptor
beads, followed by incubation and detection. Data represent mean and
SD for ≥3 samples. Top and bottom panels represent two separate
experiments with different ranges of dilution.
Additional file 3: Figure S3. Alpha donor and acceptor bead
concentrations and ratios for detection of ubiquitinated PCNA. a
Concentrations of donor and acceptor beads were varied, as indicated,
followed by incubation and detection. Data represent mean and SD for 4
samples b Ratios of donor and acceptor beads (values in μg/ml) were
varied, followed by incubation and detection. Data represent mean and
SD for 7–8 samples. D = donor beads; A = acceptor beads.
Additional file 4: Figure S4. Donor and acceptor bead order of
addition for detection of ubiquitinated PCNA. The order of addition of
Alpha donor and acceptor beads was examined, with incubation for 2 h
with one and then further for 2 h after addition of the other (compared
to simultaneous addition and incubation for 2 h or 4 h), followed by
detection. Data represent mean and SD for 3 samples. D = donor beads;
A = acceptor beads.
Additional file 5: Figure S5. Donor and acceptor bead incubation
times for detection of ubiquitinated PCNA. Times of incubation with
beads prior to Alpha detection were evaluated. Data represent mean and
SD for 3 samples. a Incubation time course with donor and acceptor
bead concentrations at 20 μg/ml each. b Incubation time course with
donor and acceptor bead concentrations at 10 μg/ml each for Alpha
detection after PCNA ubiquitination reaction in the presence and
absence of ATP, the latter to test whether any non-specific precipitation
or other effects would by themselves influence subsequent signal over
time. D = donor beads; A = acceptor beads.
Additional file 6: Figure S6. Variation of ATP concentration and DMSO
tolerance in Alpha assay for PCNA ubiquitination. a ATP concentrations
for the PCNA ubiquitination cascade were varied, followed by incubation
and detection. Data represent mean and SD for 3 samples. b Different
concentrations of DMSO were added to the reactions, followed by
incubation and detection. Data represent mean and SD for 3 samples.
Additional file 7: Figure S7. a Split two-part Rad6~ubiquitin thioester
formation assay, with precharging of Uba1 with biotin-ubiquitin prior to
addition of Rad6 and quenching of Uba1 charging with EDTA to a final
concentration of 20 mM (added between steps to chelate Mg2+ and
prevent further ATP-dependent Uba1 charging with ubiquitin); negative
control was without ATP, while the positive control and EDTA-treated
samples included ATP. Data represent mean and SD for 8 samples. b
Modified two-part Rad6~ubiquitin thioester formation assay reaction with
250 μM ATP and 500 μM MgCl2, with Uba1 quenching with varying
concentrations of EDTA. Data represent mean and SD for 3 samples. c
Two-part Rad18 autoubiquitination assay with 250 μM ATP and 500 μM
MgCl2, with Uba1 charging quenched by adding EDTA to 1 mM, followed
by addition of 100 nM Rad6–Rad18 dimer and 50 nM or 100 nM FLAG-
Rad18. Data represent mean and SD for 4 samples.
Additional file 8: Figure S8. SDS–polyacrylamide gel of proteins used
in this study. Proteins were resolved on a 12% SDS–polyacrylamide gel
and stained with Coomassie Brilliant Blue R-250. Each lane represents a
different protein preparation, and the relevant protein bands are
indicated with arrow marks. Note: The 5 subunits of S. cerevisae RFC were
only resolved into 3 bands, since the molecular weights of the larger of
the three of the smaller subunits are so close to each other.
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